Table 3.

Wound healing outcomes using allogeneic dermal TESSs in clinical studies for RDEB

References	Study type	Patients (N)	Type of TESS	Follow-up	Outcome
[61]	Prospective study	3	Dermal fibroblasts grown on a bilayered spongy matrix of atelo-collagen and HA	4 weeks	Twice weekly grafting for 2–6 weeks increased wound granulation and epithelialisation at edges of the grafted areas. Only a short follow-up reported
[17]	Case report	2		3–4 weeks	Twice weekly grafting for 2 weeks followed by weekly grafting resulted in full epithelialisation after 3–4 weeks for both patients. However, no detectable increase in C7 was observed and only a short follow-up was conducted
[63]	Case report	6	Commercially available cultured dermal substitute DermaGraft® (Organogenesis, Canton, MA, USA) consisting of fibroblasts grown within a polyglactin scaffold	8 weeks	74% average epithelialisation across all graft sites but no longer follow-up reported
[62]	Pilot study	7	Dermal fibroblasts cultured on decellularised amniotic membrane scaffolding	12 weeks	Reduced wound size of at least 70% for 6 out of 21 wounds (28%). Only one wound completely healed. No longer follow-up reported

C7 type VII collagen, HA hyaluronic acid, TESS tissue-engineered skin substitute